uniQure N.V. Faces Securities Fraud Class Action After FDA Delay Triggers 49% Stock Price Drop

uniQure N.V. Securities Fraud Class Action

uniQure N.V., a biotechnology company specializing in gene therapies, has recently come under fire due to a class action lawsuit centered around securities fraud. This legal battle is a direct response to an alarming situation that resulted from the U.S. Food and Drug Administration's (FDA) delayed decision regarding one of uniQure's leading drug candidates, AMT-130. The fallout from this delay has had a substantial financial impact on the company and its investors.

The lawsuit, currently ongoing in the United States District Court for the Southern District of New York, highlights a period where uniQure and its executives allegedly failed to disclose critical information to shareholders. Specifically, between September 24 and October 31, 2025, the company conveyed confidence that the FDA would fast-track the approval of AMT-130 following a Biologics License Application (BLA) submission in early 2026. However, this optimism was abruptly shattered on November 3, 2025.

On that fateful day, uniQure revealed that the FDA had reevaluated the adequacy of the data from Phase I/II studies of AMT-130, suggesting it was no longer sufficient to support their submission for accelerated approval. This announcement sent shockwaves through the market, and the aftermath was dire—uniQure's stock plunged by over 49%, dropping from $67.69 to an alarming $34.29 per share in just one day.

The velocity of this decline raised immediate concerns among investors, prompting research into potential regulatory missteps and miscommunications. Kenneth Swick, a noted securities litigation attorney from Kahn Swick & Foti, LLC, has been vocal about aiding affected investors. He emphasizes the importance of filing lead plaintiff applications by April 13, 2026, for those who incurred substantial losses during the class period, as they prepare to build their case against uniQure.

Legal experts are closely monitoring the situation, highlighting that this case exemplifies the importance of transparency and accountability in publicly traded companies, especially in the critical healthcare sector where patient lives hang in the balance. KSF has urged investors to reach out without obligation to discuss their legal rights regarding potential remedies for the losses they've suffered.

For uniQure shareholders, this development is a stark reminder of the volatility inherent in biotechnology investments, where clinical trials and regulatory approvals can dramatically affect stock performance. The outcomes of this lawsuit could set significant precedents in the arena of securities fraud and investor rights, shedding light on the responsibilities of biotech firms in disclosing vital information to their stakeholders.

Looking forward, this case promises to be a critical junction not just for uniQure’s future, but also for its investors and the broader market in assessing how disclosures are managed amid fluctuating trial outcomes and FDA interactions. Those with stakes in uniQure are advised to remain alert and engaged with ongoing legal proceedings to safeguard their interests during this tumultuous time.